Disease index

idiopathic pulmonary fibrosis

Respiratory · 2015–2024

8decisions
2medicines
7carried consumer input
185individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
nintedanib Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with a progressive phenotype (PF-ILD). Nov 2024 Not recommended input received
pirfenidone Treatment of idiopathic pulmonary fibrosis (IPF). This submission was for new tablet forms (267 mg and 801 mg) as formulation changes to the previously listed… Mar 2018 Recommended with restriction none received
pirfenidone Idiopathic pulmonary fibrosis (IPF) in patients aged 40 years or older with confirmed diagnosis, FVC ≥50% predicted, and DLCO ≥30% predicted. Mar 2016 Not recommended 1 individuals
nintedanib Treatment of patients with idiopathic pulmonary fibrosis (IPF), specifically mild to moderate IPF. Nov 2016 Recommended 33 individuals
pirfenidone Treatment of idiopathic pulmonary fibrosis (IPF) in patients with confirmed diagnosis, FVC ≥50% predicted, and DLCO ≥30% predicted, aged 40 years or older. Nov 2016 Deferred 50 individuals
nintedanib Treatment of idiopathic pulmonary fibrosis (IPF) in adult patients aged 40 years and over with mild to moderate disease. Mar 2015 Not recommended 3 individuals
nintedanib Treatment of idiopathic pulmonary fibrosis (IPF), specifically mild to moderate IPF in patients aged 40 years or older with confirmed diagnosis and adequate… Nov 2015 Deferred 50 individuals
pirfenidone Treatment of idiopathic pulmonary fibrosis (IPF) in patients with confirmed diagnosis, HRCT findings consistent with IPF, FVC ≥50% predicted, and DLCO ≥30%… Nov 2015 Recommended with restriction 48 individuals

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.